Table 1 Baseline characteristics of the patients according to the current and extended criteria.

From: Survival of lung cancer patients according to screening eligibility using Korean Lung Cancer Registry 2014–2016

Variables

Current criteria

Extended criteria

Extended age

Extended smoking

n = 1978

n = 586

n = 338

n (%)

n (%)

p-valuea

n (%)

p-valuea

Age, years, (mean ± SD)

65.7 ± 5.6

72.8 ± 9.7

< 0.001

65.5 ± 5.9

0.682

50–53

0 (0.0)

99 (16.9)

–

0 (0.0)

–

54–74

1978 (100)

0 (0.0)

338 (100)

75–80

0 (0.0)

487 (83.1)

0 (0.0)

Sex

 Female

52 (2.6)

20 (3.4)

0.386

26 (7.7)

< 0.001

 Male

1926 (97.4)

566 (96.6)

312 (92.3)

Diagnostic path

 Without symptoms

679 (34.3)

153 (26.1)

< 0.001

131 (38.8)

0.129

 With symptoms

1299 (65.7)

433 (73.9)

207 (61.2)

Smoking pack-years (mean ± SD)

49.8 ± 22.2

51.6 ± 19.3

 

22.4 ± 2.8

 

 20–29

0 (0.0)

0 (0.0)

0.058

338 (100.0)

<0.001

 ≥ 30

1978 (100)

586 (100)

0 (0.00)

Tumor stageb

NSCLC

1578 (80.4)

456 (76.5)

 

279 (81.3)

 

 I

373 (23.6)

84 (18.4)

0.074

73 (26.2)

 0.559

 II

173 (11.0)

47 (10.3)

26 (9.3)

 III

381 (24.1)

128 (28.1)

72 (25.8)

 IV

651 (41.3)

197 (43.2)

108 (38.7)

SCLC

385 (19.6)

140 (23.5)

 

64 (18.7)

 

 Limited

143 (37.1)

51 (39.8)

0.659

18 (31.6)

 0.505

 Extensive

242 (62.9)

77 (60.2)

39 (68.4)

Morphology

 Squamous

706 (35.7)

226 (38.6)

0.048

98 (26.2)

0.006

 Adenocarcinoma

687 (34.7)

171 (29.2)

150 (44.4)

 Small cell

389 (19.7)

129 (22.0)

57 (16.9)

 NSCLC otherc

116 (5.9)

43 (7.3)

24 (7.1)

 Otherd

80 (4.0)

17 (2.9)

9 (2.7)

  1. SD, Standard deviation; NSCLC, non–small cell lung carcinoma; SCLC, small cell lung cancer. aThe distribution was compared to patients in the current criteria group. bThe frequency of known tumor stages in NSCLC and SCLC are presented; the frequency of unknown stage in the current criteria, extended age, and extended smoking groups were 15 (0.7%), 2 (0.3%), and 2 (0.5%), respectively. cPatients who had large cell carcinoma, more than one NSCLC, and non-specified NSCLC are included. dPatients who had carcinoid and both NSCLC and SCLC are included.
Back to article page